Clinical trials: Refractory Neoplasm
Hematological Malignancy, Lymphoma
SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.
This is a phase Ia/Ib, first-in-Human, open-Label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy…
- Trial name
- NCT05293912
- Testing
- SG2501
- Where
- 8 sites in United States
- Volunteers
- 2 people
- Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
Mycosis Fungoides, Sezary Syndrome
Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome
The purpose of this study is to determine the efficacy of the drug, HuMax-CD4, in patients with mycosis fungoides(MF) and sezary syndrome who are intolerant to or do not respond to treatment with Targretin® and one other standard…
- Trial name
- NCT00127881
- Testing
- HuMax-CD4 (zanolimumab)
- Where
- 35 sites in United States, France and 3 more
- Volunteers
- 76 people
- Sponsor
- Emergent Product Development Seattle LLC
EBV Associated Lymphoid Neoplasms
GP350 CAR-T for Relapse/Refractory and Epstein-Barr Virus Infection Associated Lymphoid Neoplasms
This is a Phase 1/Phase 2 open-label, single-arm clinical study of GP350 CAR-T for Relapse/Refractory and Epstein-Barr virus infection associated lymphoid neoplasms.
- Trial name
- ANXIN-02 (NCT07306156)
- Testing
- GP350 CAR-T
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Zhimin Zhai
Leukemia, Myeloid
High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML
The purpose of this study is to evaluate the safety and efficiency of high dose allogeneic mismatched hematopoietic stem cells infusions after normal chemotherapy in patients with relapsed/refractory acute myeloid leukemia（AML）.
- Trial name
- NCT03080922
- Testing
- hematopoietic stem cell
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Melanoma, Carcinoma, Non-Small- Cell Lung
A Study of SEA-CD40 Given With Other Drugs in Cancers
This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug. There are 2 parts in this trial.
- Trial name
- NCT04993677
- Testing
- SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed
- Where
- 29 sites in United States, Canada and 4 more
- Volunteers
- 77 people
- Sponsor
- Seagen Inc.
Central Nervous System Neoplasm, Solid Neoplasm
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
This phase I trial studies the side effects and best dose of trebananib in treating patients with solid tumors that has returned after a period of improvement or does not respond to treatment, including central nervous system…
- Trial name
- NCT01538095
- Testing
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 22 sites in United States, Canada
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma
Elranatamab is a bispecific antibody: binding of elranatamab to CD3- expressing T-cell and BCMA- expressing multiple myeloma cells causes targeted T-cell mediated cytotoxicity.
- Trial name
- MAGNETISMM17 (NCT05462639)
- Testing
- Elranatamab (PF-06863135)
- Where
- 36 sites in United States, Canada
- Sponsor
- Pfizer
Non-Hodgkin's Lymphoma
Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)
The purpose of the study is to find out the effects and the safety of an investigational study drug called LBH589 when given to people with relapsed or refractory chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL).
- Trial name
- NCT01090973
- Testing
- LBH589
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Metastatic Breast Cancer, Advanced Breast Cancer
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer
This study aims to evaluate the efficacy and safety of U3-1402 in participants with advanced breast cancer (ABC). Participants have to be hormone-receptor positive (HR+) and have to be resistant to endocrine therapy and…
- Trial name
- ICARUS BREAST (NCT04965766)
- Testing
- U3-1402
- Where
- 11 sites in France
- Volunteers
- 139 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Lung Neoplasms
Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer
The purpose of this study is to determine whether nintedanib (vargatef®) combined with docetaxel are effective in second line of treatment in patients with no squamous non small cell lung cancer refractory to first line…
- Trial name
- REFRACT (NCT02531737)
- Testing
- vargatef®, Docetaxel
- Where
- 11 sites in France
- Volunteers
- 59 people
- Sponsor
- University Hospital, Limoges
Pediatric Cancers, Solid Tumor Pediatric
Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors
A Phase 1 clinical trial to evaluate the safety and early efficacy of CAR T-cells with IL-7Ra signal targeting B7H3 in children with solid tumors patients after complete standard treatments.
- Trial name
- CMD03 (NCT06612645)
- Testing
- B7H3-IL7Ra CAR-T cells
- Where
- Thailand
- Volunteers
- 9 people
- Sponsor
- Chulalongkorn University
Refractory Meningioma
Semi-automated Segmentation Methods of SSTR PET for Dosimetry Prediction
Tumor dosimetry with somatostatin receptor-targeted peptide receptor radionuclide therapy (SSTR-targeted PRRT) by 177Lutetium-DOTATATE might contribute to improve follow-up and treatment response of refractory meningiomas.
- Trial name
- 177Lumen (NCT05537675)
- Testing
- To evaluate the SUVmean (Standard Uptake Value) as a predictive factor of the tumor absorbed dose compared to the SUVmax
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Central Hospital, Nancy, France
Hepatocellular Carcinoma
Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors
The CaPture trial is a prospective, multi-centre, non-randomized phase II study. Its aim is to assess feasibility, safety and efficacy signals of Cabozantinib treatment in patients with HCC and prior non-response or disease…
- Trial name
- CaPture (NCT04767906)
- Testing
- Cabozantinib
- Where
- 5 sites in Germany
- Volunteers
- 16 people
- Sponsor
- University of Leipzig
NHL, Leukemia
First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML
This Trial is a FIH, open-label, multicenter trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ETH-155008 in subjects with R/R B-cell NHL, CLL/SLL and AML who previously received standard…
- Trial name
- NCT04840784
- Testing
- ETH-155008
- Where
- 5 sites in Australia
- Volunteers
- 9 people
- Sponsor
- Shengke Pharmaceuticals Pty Ltd
Multiple Myeloma
Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients
This study will evaluate the safety and the efficacy of the association of Melphalan/ Prednisone/Thalidomide/Defibrotide (MPTD) as salvage treatment in advanced and refractory myeloma patients.
- Trial name
- MPTD (NCT00406978)
- Testing
- Prednisone, Melphalan, Thalidomide
- Where
- 5 sites in Italy
- Volunteers
- 24 people
- Sponsor
- Silvio Aime
Solid Tumors, Children
A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults
The aim of this clinical study is to determine the efficacy and safety of the liposomal mitoxantrone combination regimen in treating relapsed and refractory solid tumors among children, adolescents, and young adults.
- Conditions
- Solid Tumors, Children, Adolescents
- Trial name
- NCT06761417
- Testing
- Mitoxantrone liposome, Capecitabine, Anlotinib
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma
A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma
This phase II trial studies how well giving panobinostat together with lenalidomide works in treating patients with relapsed or refractory Hodgkin lymphoma.
- Conditions
- Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma
- Trial name
- NCT01460940
- Testing
- panobinostat, lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
AML - Acute Myeloid Leukemia, AML With Mutated NPM1
Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation
The goal of this clinical trial is to test BSB-2002 which is a new type of cellular therapy to treat blood cancer (AML). It will evaluate the safety of BSB-2002 and also determine whether it works to prevent relapse of your…
- Conditions
- AML - Acute Myeloid Leukemia, AML With Mutated NPM1, AML, Adult Recurrent
- Trial name
- NCT07566585
- Testing
- SOC+ BSB-2002, SOC+BSB-2002
- Where
- United States
- Sponsor
- BlueSphere Bio, Inc
Non-Hodgkin Lymphoma
Identification of the Best Treatment Pathway for Patients With Relapsed/Refractory Lymphocytic B-derived Non-Hodgkin Lymphoma
Bispecific antibodies have demonstrated high efficacy in the treatment of Refractory/relapsed b-cell non-Hodgkin lymphomas. However, a non-negligible percentage of patients do not respond to therapy and/or develop significant…
- Trial name
- ASCLEPIO (NCT07614035)
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lymphoma
Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell Lymphoma
The goal of this clinical research study is to evaluate effectiveness and safety of ChiCGB regimen( chidamide, cladribine, gemcitabine and busulfan).
- Trial name
- NCT03151876
- Testing
- Chidamide, Cladribine, gemcitabine
- Where
- 18 sites in China
- Volunteers
- 93 people
- Sponsor
- Sichuan University
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.